Reviewed & Fact-Checked by getCoverageNow Editorial Team
GCN Medical & Insurance Compliance Advisory Group • Updated July 2026
The single biggest question in health insurance for 2026 is coverage for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound. While these revolutionary drugs are life-changing for many patients, their extreme cost ($1,000+ per month) has caused insurance companies to rapidly tighten their approval rules.
Sponsored Resource
New 2026 Coverage Criteria
In 2026, almost all insurers now require strict 'Step Therapy'. This means you must prove you have tried older, cheaper weight-loss medications (or medically supervised diet programs) for at least 3-6 months and failed, before the insurance will approve the expensive GLP-1s. Furthermore, your Body Mass Index (BMI) must typically be over 30, or over 27 with a related comorbidity like clinically diagnosed high blood pressure or type 2 diabetes.
Clinical Insight: The Pre-Authorization Battle
As a prescribing physician, the "Prior Authorization" (PA) process for these drugs is currently the hardest hurdle. Your doctor must submit extensive bloodwork and chart notes to the insurance company. If your insurance denies the initial PA, do not give up. You and your doctor have the legal right to file an appeal. Over 40% of first-time denials for GLP-1s are overturned on appeal when the doctor provides supplementary clinical evidence.
Which plans offer the best coverage?
Large, employer-sponsored PPO plans currently have the highest GLP-1 approval rates. If you are buying on the ACA Marketplace, you must read the "Formulary" (the drug list) before buying a plan. Look specifically for plans that list 'Weight Loss Management' or 'Anti-Obesity Medications' as covered benefits. Note: Medicare by law still does not cover GLP-1s purely for weight loss, but will cover them if you are diagnosed with Type 2 Diabetes or specific cardiovascular risks.